Q1 2025 Vertex Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Vertex Pharmaceuticals Inc (VRTX) reported a 3% year-over-year revenue growth, reaching $2.77 billion in Q1 2025.
- The company successfully launched ALYFTREK, a new CF medicine, and JOURNAVX, a novel non-opioid for acute pain, both receiving positive feedback.
- VRTX is expanding its patient base with the global launch of CASGEVY, a gene-edited therapy for sickle cell disease and beta-thalassemia.
- The company is advancing its R&D pipeline with four programs in pivotal development, setting up potential filings in 2026.
- VRTX raised the low end of its 2025 total revenue guidance, now expecting $11.85 billion to $12 billion, indicating confidence in continued growth.
- Ex-US revenue declined by 5% year-over-year, impacted by an illegal copy product in Russia.
- Non-GAAP operating income decreased from $1.34 billion in Q1 2024 to $1.18 billion in Q1 2025, primarily due to increased operating expenses.
- The Phase 1/2 study of VX-522 for CF patients was temporarily paused due to a tolerability issue, delaying progress.
- The company faces challenges in securing broad and sustainable payer coverage for JOURNAVX, impacting early revenue realization.
- Gross to net for JOURNAVX is significantly impacted by patient assistance programs, affecting early financial performance.
Good day, and welcome to the Vertex Pharmaceuticals first quarter 2025 earnings call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Ms. Susie Lisa. Please go ahead, ma'am.
Good evening, all. My name is Susie Lisa, and as the Senior Vice President of Investor Relations. It is my pleasure to welcome you to our first quarter 2025 financial results conference call. On tonight's call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and President; Stuart Arbuckle, Chief Operating Officer; Charlie Wagner, Chief Financial Officer; and Duncan McKechnie, SVP North America Commercial Operations and come July 1, Chief Commercial Officer.
We recommend that you access the webcast slides as you listen to this call. The call is being recorded, and a replay will be available on our website. We will make forward-looking statements on this call that are subject to the risks and uncertainties
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
